A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2

The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high morbidity and mortality rates reported amongst a vulnerable subset of patients termed high risk. While vaccines remain the primary option for COVID-19 prevention, neutralizing monoclonal antibodies (mAbs), such...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Ramesh, Shawa, Imad, De La Torre, Inmaculada, Pustizzi, Jennifer M., Haustrup, Natalie, Patel, Dipak R., Huhn, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353431/
https://www.ncbi.nlm.nih.gov/pubmed/34374951
http://dx.doi.org/10.1007/s40121-021-00515-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353431/
https://www.ncbi.nlm.nih.gov/pubmed/34374951
http://dx.doi.org/10.1007/s40121-021-00515-6

Ejemplares similares